{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T08:01:27Z","timestamp":1782979287638,"version":"3.54.5"},"reference-count":30,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jdiacomp.2022.108315","type":"journal-article","created":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T11:33:36Z","timestamp":1664019216000},"page":"108315","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Association between first-line monotherapy with metformin and the risk of atrial fibrillation (AMRAF) in patients with type 2 diabetes"],"prefix":"10.1016","volume":"36","author":[{"given":"Anira","family":"Iqbal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehra","family":"Tekin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Kattan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinge","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Milinovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Pantalone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Zimmerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina K.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeta R.","family":"Kashyap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2022.108315_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjcard.2011.03.004","article-title":"Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation","author":"Huxley","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jdiacomp.2022.108315_bb0010","doi-asserted-by":"crossref","DOI":"10.1001\/jama.1994.03510350050036","article-title":"Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham heart study","author":"Benjamin","year":"1994","journal-title":"JAMA J Am Med Assoc"},{"key":"10.1016\/j.jdiacomp.2022.108315_bb0015","first-page":"853","article-title":"Endothelial dysfunction in diabetes mellitus","volume":"3","author":"Hadi","year":"2007","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.jdiacomp.2022.108315_bb0020","doi-asserted-by":"crossref","DOI":"10.1161\/01.CIR.98.10.946","article-title":"Impact of atrial fibrillation on the risk of death: the Framingham heart study","author":"Benjamin","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2022.108315_bb0025","doi-asserted-by":"crossref","unstructured":"J. P. Piccini B. G. Hammill M. F. Sinner P. N. Jensen A. F. Hernandez S. R. Heckbert E. J. Benjamin L. H. Curtis Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993-2007. n.d. Circ Cardiovasc Qual Outcomes 5(1), 85\u201393. doi:10.1161\/CIRCOUTCOMES.111.962688.","DOI":"10.1161\/CIRCOUTCOMES.111.962688"},{"key":"10.1016\/j.jdiacomp.2022.108315_bb0030","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s00018-020-03648-y","article-title":"Effect of antidiabetic drugs on the risk of atrial fibrillation: mechanistic insights from clinical evidence and translational studies","volume":"78","author":"Lee","year":"2021","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.jdiacomp.2022.108315_bb0035","doi-asserted-by":"crossref","unstructured":"S. Dublin N. L. Glazer N. L. Smith B. M. Psaty T. Lumley K. L. Wiggins R. L. Page S. R. Heckbert Diabetes mellitus, glycemic control, and risk of atrial fibrillation. n.d. J Gen Intern Med 25(8), 853\u2013858. doi:10.1007\/s11606-010-1340-y.","DOI":"10.1007\/s11606-010-1340-y"},{"key":"10.1016\/j.jdiacomp.2022.108315_bb0040","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12933-016-0369-6","article-title":"Oxidative stress, inflammation, endothelial dysfunction and incidence of type 2 diabetes","volume":"24","author":"Odegaard","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2022.108315_bb0045","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3389\/fphys.2019.00135","article-title":"The association between diabetes mellitus and atrial fibrillation: clinical and mechanistic insights","volume":"10","author":"Bohne","year":"2019","journal-title":"Front Physiol"},{"key":"10.1016\/j.jdiacomp.2022.108315_bb0050","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12933-019-0983-1","article-title":"Risk of atrial fibrillation in persons with type 2 diabetes and the excess risk in relation to glycaemic control and renal function: a Swedish cohort study","volume":"19","author":"Seyed Ahmadi","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2022.108315_bb0055","doi-asserted-by":"crossref","unstructured":"A. S. Go E. M. Hylek K. A. Phillips Y. Chang L. E. Henault J. V. Selby D. E. Singer Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. n.d. JAMA, 285(18), 2370\u20132375. doi:10.1001\/jama.285.18.2370.","DOI":"10.1001\/jama.285.18.2370"},{"key":"10.1016\/j.jdiacomp.2022.108315_bb0060","doi-asserted-by":"crossref","unstructured":"O. Fatemi E. Yuriditsky C. Tsioufis D. Tsachris T. Morgan J. Basile T. Bigger W. Cushman D. Goff E. Z. Soliman A. Thomas V. Papademetriou Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). n.d. Am J Cardiol 114(8), 1217\u20131222. doi:10.1016\/j.amjcard.2014.07.045.","DOI":"10.1016\/j.amjcard.2014.07.045"},{"key":"10.1016\/j.jdiacomp.2022.108315_bb0065","doi-asserted-by":"crossref","unstructured":"T. F. Chao H. B. Leu C. C. Huang J. W. Chen W. L. Chan S. J. Lin S. A. Chen Thiazolidinediones can prevent new onset atrial fibrillation in patients with non-insulin dependent diabetes. n.d. Int J Cardiol 156(2), 199\u2013202. doi:10.1016\/j.ijcard.2011.08.081.","DOI":"10.1016\/j.ijcard.2011.08.081"},{"key":"10.1016\/j.jdiacomp.2022.108315_bb0070","doi-asserted-by":"crossref","unstructured":"Z. Zhang X. Zhang P. Korantzopoulos K. P. Letsas G. Tse M. Gong L. Meng G. Li T. Liu Thiazolidinedione use and atrial fibrillation in diabetic patients: a meta-analysis. n.d. BMC Cardiovasc Disord 17(1), 96. doi:10.1186\/s12872-017-0531-4.","DOI":"10.1186\/s12872-017-0531-4"},{"key":"10.1016\/j.jdiacomp.2022.108315_bb0075","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.hepres.2005.09.027","article-title":"Thiazolidinediones: pleiotropic drugs with potent anti-inflammatory properties for tissue protection","volume":"33","author":"Buckingham","year":"2005","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jdiacomp.2022.108315_bb0080","doi-asserted-by":"crossref","unstructured":"J. L. Pallisgaard T. B. Lindhardt L. Staerk J. B. Olesen C. Torp-Pedersen M. L. Hansen G. H. Gislason Thiazolidinediones are associated with a decreased risk of atrial fibrillation compared with other antidiabetic treatment: a nationwide cohort study. n.d. Eur Heart J Cardiovasc Pharmacother 3(3), 140\u2013146. doi:10.1093\/ehjcvp\/pvw036.","DOI":"10.1093\/ehjcvp\/pvw036"},{"key":"10.1016\/j.jdiacomp.2022.108315_bb0085","doi-asserted-by":"crossref","unstructured":"Y. S. Liou F. Y. Yang H. Y. Chen G. P. Jong Antihyperglycemic drugs use and new-onset atrial fibrillation: a population-based nested case control study. n.d. PloS one, 13(8), e0197245. doi:10.1371\/journal.pone.0197245.","DOI":"10.1371\/journal.pone.0197245"},{"key":"10.1016\/j.jdiacomp.2022.108315_bb0090","doi-asserted-by":"crossref","unstructured":"M. Emdin A. Gastaldelli E. Muscelli A. Macerata A. Natali S. Camastra E. Ferrannini Hyperinsulinemia and autonomic nervous system dysfunction in obesity: effects of weight loss. n.d. Circulation, 103(4), 513\u2013519. doi:10.1161\/01.cir.103.4.513.","DOI":"10.1161\/01.CIR.103.4.513"},{"key":"10.1016\/j.jdiacomp.2022.108315_bb0095","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00592-021-01841-4","article-title":"Metformin versus sulphonylureas for new onset atrial fibrillation and stroke in type 2 diabetes mellitus: a population-based study","volume":"59","author":"Zhou","year":"2022","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.jdiacomp.2022.108315_bb0100","doi-asserted-by":"crossref","unstructured":"M. Monami B. Nreu A. Scatena S. Giannini F. Andreozzi G. Sesti E. Mannucci Glucagon-like peptide-1 receptor agonists and atrial fibrillation: a systematic review and meta-analysis of randomised controlled trials. n.d. J Endocrinol Investig 40(11), 1251\u20131258. doi:10.1007\/s40618-017-0698-7.","DOI":"10.1007\/s40618-017-0698-7"},{"key":"10.1016\/j.jdiacomp.2022.108315_bb0105","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S2213-8587(15)00233-8","article-title":"Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis [published correction appears in Lancet Diabetes Endocrinol. 2015 Oct;3(10):e8]","volume":"3","author":"Fisher","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jdiacomp.2022.108315_bb0110","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1210\/jc.2004-0019","article-title":"The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial","volume":"89","author":"Caballero","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jdiacomp.2022.108315_bb0115","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1161\/CIRCRESAHA.116.308445","article-title":"Anti-inflammatory effects of metformin irrespective of diabetes status","volume":"119","author":"Cameron","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.jdiacomp.2022.108315_bb0120","doi-asserted-by":"crossref","first-page":"196","DOI":"10.2174\/1871530315666150316124019","article-title":"Metformin and inflammation: its potential beyond glucose-lowering effect","volume":"15","author":"Saisho","year":"2015","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"10.1016\/j.jdiacomp.2022.108315_bb0125","doi-asserted-by":"crossref","unstructured":"J. Wang L. Zhu K. Hu Y. Tang X. Zeng J. Liu J. Xu Effects of metformin treatment on serum levels of C-reactive protein and interleukin-6 in women with polycystic ovary syndrome: a meta-analysis: a PRISMA-compliant article. n.d. Medicine, 96(39), e8183. doi:10.1097\/MD.0000000000008183.","DOI":"10.1097\/MD.0000000000008183"},{"key":"10.1016\/j.jdiacomp.2022.108315_bb0130","doi-asserted-by":"crossref","unstructured":"S. H. Chang L. S. Wu M. J. Chiou J. R. Liu K. H. Yu C. F. Kuo M. S. Wen W. J. Chen Y. H. Yeh L. C. See Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies. n.d. Cardiovasc Diabetol 13, 123. doi:10.1186\/s12933-014-0123-x.","DOI":"10.1186\/s12933-014-0123-x"},{"key":"10.1016\/j.jdiacomp.2022.108315_bb0135","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/amiajnl-2011-000439","article-title":"Use of diverse electronic medical record systems to identify genetic risk for type 2 diabetes within a genome-wide association study","volume":"19","author":"Kho","year":"2012","journal-title":"J Am Med Inform Assoc"},{"key":"10.1016\/j.jdiacomp.2022.108315_bb0140","doi-asserted-by":"crossref","unstructured":"K. M. Pantalone T. M. Hobbs B. J. Wells S. X. Kong M. W. Kattan J. Bouchard K. M. Chagin C. Yu B. Sakurada A. Milinovich W. Weng J. M. Bauman R. S. Zimmerman Changes in characteristics and treatment patterns of patients with newly diagnosed type 2 diabetes in a large United States integrated health system between 2008 and 2013. Clinical medicine insights. n.d. Endocrinol Diabetes, 9, 23\u201330. doi:10.4137\/CMED.S39761.","DOI":"10.4137\/CMED.s39761"},{"key":"10.1016\/j.jdiacomp.2022.108315_bb0145","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1002\/sim.7501","article-title":"Practical recommendations for reporting fine-gray model analyses for competing risk data","volume":"36","author":"Austin","year":"2017","journal-title":"Stat Med"},{"key":"10.1016\/j.jdiacomp.2022.108315_bb0150","first-page":"1","article-title":"Mice: multivariate imputation by chained equations in R","volume":"45","author":"Van Buuren","year":"2011","journal-title":"Journal of Statistical Software"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872722002276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872722002276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:16:27Z","timestamp":1761005787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872722002276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1056872722002276"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2022.108315","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between first-line monotherapy with metformin and the risk of atrial fibrillation (AMRAF) in patients with type 2 diabetes","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2022.108315","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022","name":"copyright","label":"Copyright"}],"article-number":"108315"}}